What question did this study set out to answer?

To describe a case of acquired reactive perforating collagenosis that developed after cabozantinib treatment.

April 10, 2026

Acquired Reactive Perforating Collagenosis following Cabozantinib – a case report

Key Points

To describe a case of acquired reactive perforating collagenosis that developed after cabozantinib treatment.
Case report detailing patient treatment history and outcomes
Analysis of dermatological symptoms post-treatment
Documented occurrence of reactive perforating collagenosis in the patient
Noted improvement in skin condition after cessation of cabozantinib

Abstract

RG reports consultancy, speaker fees, research or travel grants from or for Amgen, Sanofi-Regeneron, Merck-Serono, MSD, Kyowa-Kirin, Almirall, SUN Pharma, Recordati, BMS, Pierre-Fabre, Delcath, Janssen, Novartis.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Nina Flatt

Johannes Wesling Klinikum Minden

Elke Lusmöller

Johannes Wesling Klinikum Minden

Rudolf Stadler

Johannes Wesling Klinikum Minden

Journals

JDDG Journal der Deutschen Dermatologischen Gesellschaft

Actions

Institutions

Johannes Wesling Klinikum Minden

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Acquired Reactive Perforating Collagenosis following Cabozantinib – a case report

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study